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О, сколько нам открытий чудных 
Готовят просвещенья дух 
И опыт, сын ошибок трудных, 
И гений, парадоксов друг, 
И случай, бог изобретатель. 
 
А.С. Пушкин 
 
Oh, how many wondrous revelations 
Prepares for us the spirit of enlightenment, 
Experience, the son of painful errors, 
And genius, the paradoxes’ friend, 
And god of all inventions - simple chance. 
 
A.S. Pushkin (translation from Russian) 
 
 
  
 
 
 
  
 
 
Abstract 
Poor physicochemical properties of pharmaceutical solids significantly restrain both pre-
clinical development and clinical translation of investigational new drugs. Scientific 
studies that disclose more solid-state forms of a given drug compound are therefore very 
important for pharmaceutical industry. In regard to this, the need for effective solid-form 
screening approaches, especially designed for the early discovery phases, is widely 
recognized. The goal of the studies presented in this thesis is to elaborate an approach to 
expand the diversity of the solid-state forms of weak bases and enable efficient tailoring of 
their properties, especially solubility, hygroscopicity and physical stability.  
The thesis introduces the results of a systematic research work on the discovering and 
characterizing new solid-state forms of weakly basic drug molecules. In particular, an 
effective and fast approach to initial evaluation of the polymorphism and solvatomorphism 
tendency and physical stability of drug candidates was developed. Using this approach, 
three crystalline forms, two anhydrous and one hemihydrate, of a hydrochloric salt were 
discovered. The most stable of the discovered forms, the hemihydrate, was selected for a 
future drug development. The introduced experimental procedures can be recommended 
also for evaluation of the polymorphism and solvatomorphism tendency of new chemical 
entities (“precandidates”) even prior to the final selection of a drug candidate. 
In order to enable the counterion and coformer selection for the salt and cocrystal 
formation, the exact knowledge of the crystal structure of the drugs and lead compounds is 
of particular importance. In our study, we have corrected the crystalline structure of the 
neat itraconazole, a potent antifungal drug, and the itraconazole-succinic acid cocrystal. 
The corrected data was used by us for preliminary selection of possible coformers 
promising in view of formation of cocrystals and salts with itraconazole. 
In another study, the potential of the cocrystal formation of itraconazole with C2-C10 
aliphatic dicarboxylic acids was investigated. Using a combination of two experimental 
screening techniques (solvent-drop grinding and slow evaporation), we have successfully 
synthesized the cocrystals of itraconazole with C2-C7 acids. These include anhydrous 
cocrystals (malonic, succinic, glutaric and pimelic acids), a cocrystal hydrate (adipic acid), 
and cocrystal solvates with acetone and tetrahydrofuran (oxalic acid). Most importantly, 
C7 was identified as the maximum carbon atom number of the aliphatic chain for the 
successful cocrystallization reaction between itraconazole and a dicarboxylic acid. This 
work demonstrates a wide diversity of itraconazole cocrystals with aliphatic dicarboxylic 
acids having a variety of the carbon chain lengths. This finding alone has a considerable 
conceptual and also practical value in the field of crystal engineering, putting an additional 
emphasis on the importance of the weak intermolecular interactions in the crystal structure 
cohesion. 
 A comparative evaluation of a new cocrystal of itraconazole with malonic acid and 
two new hydrochloric salts (dihydrochloride and trihydrochloride) of itraconazole has also 
been performed. The intrinsic dissolution rate, hygroscopicity, and thermodynamic 
stability were determined for the obtained solid-state forms and compared to itraconazole-
succinic acid (2:1) cocrystal. The results show that, in general, the solid-state forms with 
higher intrinsic dissolution rate are less stable. However, the new cocrystal was found to 
  
 
 
increase the dissolution rate of the parent drug by about 5-fold without compromising the 
hygroscopicity and the physical stability. This study demonstrates that, for dissolution rate 
enhancement of poorly water-soluble weak bases, cocrystallization is a more suitable 
approach than the formation of hydrochloric salts. 
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1 Introduction 
The pharmaceutical science recognized the importance of solid-state properties of drugs 
starting from 1969 (Haleblian and McCrone, 1969). The turning point in this respect was a 
dramatic event of temporary removing the Norvir drug from the market in 1998 (Bauer et 
al. 2001). The dosage forms, soft-gel capsules, contained a solution of ritonavir, protease 
inhibitor, that started to crystallize upon shelf-life into more stable undiscovered 
polymorphic form. This affected the solubility and bioavailability of the drug and 
consequently the clinical effect of the product (Bauer et al. 2001, Gardner et al. 2004). 
Since then the control and study of solid-state properties of API’s have become obligatory 
and been guided and supervised by Drug Regulatory Authorities. It is well known that 
various solid-state forms exhibit different physicochemical properties, such as apparent 
solubility, dissolution rate, chemical stability, physical stability, melting point, 
hygroscopicity, color, filterability, density, flow behavior, and many other properties 
(Byrn et al. 1995, 2010, Kato and Kohketsu 1981; Hancock et al. 2002; Brittain 2006, 
2009; Gavezzotti 2007; Henck and Byrn 2007; Bernstein 2011) The role of the solid-state 
properties of drugs is of particular importance for low soluble drug candidates (Huang and 
Tong 2004; Balbach and Korn 2004), for which a small difference in solubility can 
significantly affect the bioavailablity of the drug (Higuchi et al. 1963; Aguiar and Zelmer 
1969; Stahly 2007). Since high throughput screening and combinatorial synthesis 
methodology has been incorporated into the drug discovery process, number of drug 
candidates having low aqueous solubility grows constantly (Lipinski 2000). Thus there is 
a growing need to optimize and control solid state properties as early as possible.   
Ideally, the in-vivo efficiency, pharmacokinetics, and toxicology studies of low soluble 
drug candidates should be performed with the drug candidates that exhibit optimal solid-
state properties (Huang and Tong 2004; Steele 2009). This means that the most 
appropriate time for finding the most stable and soluble solid form is during the Lead 
Identification (LI) and Lead Optimization (LO) phases of the drug discovery process 
(Huang and Tong 2004; Balbach and Korn 2004; Steele 2009;). At the later stages, the 
developability assessment criteria for new drug candidates are commonly applied to 
identify the potential challenges and even project “stoppers” of the drug development 
(Huang and Tong 2004; Balbach and Korn 2004; Steele 2009). These criteria are typically 
set to solubility and dissolution, hygroscopicity, stability, and synthesis process scalability 
of the chosen solid-state form. Estimation of scalability of the synthesis process and 
physical stability includes evaluation of tendency of a new chemical entity to crystallize in 
different crystal forms, investigation of thermodynamic relationship between polymorphs 
as well as relative stability of possible polymorphic forms at ambient conditions (Llinas 
and Goodman 2008). 
On the other hand, it is of importance to optimize the drug discovery and development 
process in order to fasten the market entry of the new drugs (Hariharan et al. 2003). 
According to (Henck and Byrn 2007; Byrn et al. 2010;) one of the key elements of the 
strategy to reduce the time required for preclinical development is to link solid-form 
discovery with formulation, formulation design and manufacturing. According to the 
authors of (Henck and Byrn 2007; Byrn et al. 2010), the most efficient way to speed up 
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new drug development is to accelerate the process of the ‘proof-of-concept’ (POC). In 
their opinion, such acceleration can be achieved by performing the Best Solid Form – 
Screenings as soon as the candidate has been selected. Knowledge of the polymorphism 
and solvatomorphism tendency and solid state properties of the new candidate is of great 
importance for screening facilitation. 
To summarize, there is a need to expand the diversity of the solid-state forms to enable 
tailoring of their properties, especially solubility, in order to facilitate the selection of the 
most appropriate solid form already in the preclinical stage of the drug discovery and 
development process. The objectives of this study were (1) to obtain new developable 
forms of weakly basic drug molecules, (2) to assess the feasibility of the modeling tools 
for selecting coformers and counter-ions, (3) to develop effective screening approaches 
that can be used in industry for salts and cocrystals, (4) to evaluate the solubility, 
dissolution and stability of the new forms in order to select the solid-state forms with 
appropriate properties.  
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2 Theory and literature review 
2.1 Classification and definitions 
2.1.1 Biopharmaceutics Classification System (BCS) 
Drug substances are traditionally classified with respect to their bioavailability under four 
classes according to the Biopharmaceutics Classification System (BCS) ( Amidon et al. 
1995):  
 
• Class I – high solubility and permeability; 
• Class II – low solubility and high permeability; 
• Class III – high solubility and low permeability 
• Class IV – low solubility and low permeability 
 
The strategies for improving solubility and maximizing the dissolution rate of low 
soluble drug molecules include, for example, particle size reduction to increase the surface 
area for dissolution (Rasenack 2002; Dai et al. 2007; Barrett,Angela 2008) solubilization 
of the drug in co-solvents (Kovács et al.. 2009) and micellar solutions (Yi et al. 2007), 
complexation with cyclodextrins (Bettinetti et al. 1989; deChasteigner et al.  1996; 
Alsarra et al. 2010), formulation of amorphous form dissolved in a polymer matrix 
(Verreck et al.  2003; Six et al. 2003; Engers et al. 2010) or incorporated into porous 
particles (Mellaerts et al. 2007; Kinnari et al. 2011), the use of lipid systems for the drug 
delivery (Yi et al. 2007), and formulation of eutectic mixture of a low soluble drug and 
well soluble excipient (Liu et al. 2006). 
The best way to improve the solubility often depends on the physical and chemical 
nature of the drug. All the methods have their own strong and weak aspects as well as 
limitations and must be considered case-by-case, taking into account the scientific, 
technological and economical factors (Grant and Higuchi 1990; Steele 2009). 
In this PhD thesis the focus is on the molecules of BSC Class II drug substances 
intending to show the ways of enhancing the dissolution and solubility of drug substances 
by tailoring the appropriate solid-state form.  
 
2.1.2 Dissociation of weak electrolytes in aqueous solutions and pH 
solubility profiles of acidic and basic drug substances 
Approximately two-thirds of all existing drug substances are weak electrolytes that, in 
aqueous solution, exist as ions (Hancock et al. 2002). Such ions are formed as a result of 
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release or acceptance of protons for acids and bases, respectively. For a monoprotic acid, 
the following dissociation reaction can be written: 
 
  AOHOHHA 32 .
 
 
The degree to which the acid HA dissociates in a dilute solution is determined by the 
following equilibrium constant Ka: 
  
 HA
AOH
Ka

 3 .  
 
Here, the brackets stand for molarity (concentration in moles/liter). In the dissociation 
reaction, water acts as a base, accepting a proton from the acid. The larger is the 
dissociation constant, the stronger is the acid and, simultaneously, the higher is its 
tendency to give up a proton. For convenience, the strength of an acid is indicated by the 
value of pKa defined as 
aa KpK log . 
 
Analogously, for a monoprotic base one can write 
 
BOHHOBH   2 , 
and 
  
 BH
BH
Ka

 . 
 
Here, water acts as an acid accepting a proton from the base.  
 
To be able to use the same quantities, Ka and pKa, for both acids and bases, the protonated 
base is regarded as the corresponding acid of the free base. Owing to this, acids and bases 
are classified by using their pKa as a strength-indicating parameter, see Table 1. (Stahl 
2002). 
 
Table 1. Classification of Acids and Bases According to Strength. (Modified from (Stahl 
2002))  
 
Attribute 
pKa 
Acids Bases 
Very strong <0 14 
Strong 0-4.5 9.5-14 
Weak 4.5-9.5 4.5-9.5 
Very weak 9.5-14 0-4.5 
Extremely weak >14 <0 
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The aqueous solubility of the weak electrolyte will be maximal when all molecules are 
ionized and it will be minimal if the molecules are not ionized. Moreover, for a basic drug 
the maximum solubility will be reached at pH ≤ (pKa)base-2 and for an acidic drug at pH ≥ 
(pKa)acid+2 (Figure 1). The pH value in the human gastrointestinal tract is 1-3 in stomach, 
5-7 in duodenum and jejunum, 7-8 in ileum and rectum. Consequently, for bases having 
pKa < 6 a low solubility is expected within the whole biological pH range.  
This study has been focused on the solid-state form modification approaches for weak 
and very weak bases. 
 
 
Figure 1 Ionization % and solubility of acidic and basic drug molecule. Adopted from 
(Florence  2006). 
2.1.3 Solid-state forms 
A scheme for classification of solid-state forms of drug molecules is presented in Figure 2. 
The crystals of a given substance may vary in size and have different shapes. In other 
words, they may have the same internal, but different external structures (Zhang and Zhou 
2009). The external structure, however, does not determine the solid-state form.  
If the internal structure of a substance has a long-range order and can be described by 
the structure’s unit cell and certain elements of symmetry, the substance is crystalline. It is 
then possible to construct the crystal by repeating the unit cell in all three directions of 
space. In contrast, amorphous solids have only a short-range order and cannot be modeled 
by the above procedure. 
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Figure 2 Classification of solid-state forms. Modified from (Haleblian 1969; Zhang and Zhou 
2009;  Zavorotko et al.  2012). 
  
 
 
20 
Both amorphous and crystalline solids may be composed of a single component or a 
number of different components, chemical species. Crystalline solids composed of 
different species are called multi-component complexes or adducts (Zavorotko et al.  
2012). Thermodynamically, any adduct is always a homogeneous single phase that should 
not be confused with an inhomogeneous physical, eutectic or eutectoid mixture of several 
components. The eutectic mixture has a peculiar external structure and is characterized by 
a melting point that is always lower than the melting points of the neat components. 
Two main classes of adducts, ionic and molecular, can be defined on the basis of the 
chemical bonding between the molecules. Ionic compounds are salts, while molecular 
compounds are solvates or cocrystals. If one of the components in a molecular compound 
is liquid at normal conditions, the compound is a solvate. In case the components are 
solids at normal conditions, the compound is a cocrystal (Aakeröy and Salmon 2005; 
Bond 2007). The bonds between nonionic molecules in the crystal can be the H-bonds, π-π 
bonds between aromatic rings or, weaker but not less important, halogen and Van-der-
Waals bonds (Desiraju 2009). 
When the number of components in the compound is larger than 2, there is an option 
for the compound to form mixed types of adducts. In this case, the cocrystal salts and 
cocrystal solvates, in addition to ternary salts and cocrystals, can be formed (Zavorotko et 
al. 2012). The diversity of possible combinations will grow with the number of 
components in the crystal. It should also be emphasized, that adducts may contain more 
than one drug molecules, as well as stereo- and isomers (Childs et al. 2004; Zavorotko et 
al.  2012).  
The ability of the crystal’s components to arrange themselves in different ways in the 
crystal lattice is called polymorphism. For pure chemical elements this ability is known as 
allotropism. The polymorphism is exhibited only in solid materials. Any difference 
between polymorphs disappears when the relatively weak bonds in the crystal lattice are 
destroyed by dissolving, melting or evaporation. Both single and multi-component crystals 
may exhibit polymorphism. 
A polymorphism due to possible variations in the crystal packing is called the packing 
polymorphism. Polymorphism caused by the existence of different conformers of the same 
molecule is called conformational polymorphism (Rodriguez-Spong 2004). 
2.1.4 Salt–cocrystal continuum 
Salts belong to one of the most widely known and explored class of solid forms. Their 
physical and chemical properties are well described in many handbooks and review 
articles (Stahl 2002,  Bond et al. 2012). Approximately half of the oral drug forms contain 
the salts of active ingredients. These pharmaceutical salts are typically more rapidly and 
better soluble in stomach and intestinal juices than non-ionic species, which makes them 
advantageous components in the solid dosage forms. When the new drug candidate is a 
weak base and there is an indication of its low solubility in water, the preparation of a salt 
of this drug is automatically considered as the first choice for enhancement of its aqueous 
solubility. Moreover, purification of drug molecules during their synthesis is usually 
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performed by the salt preparation. Consequently the preparation and selection of the most 
appropriate salt is an important step in the drug development process (Stahl 2002,  Bond et 
al. 2012). 
Being discovered already more than 40 years ago, organic cocrystals still remain 
relatively unknown molecular compounds for pharmaceutical industry (Almarsson and 
Zavorotko 2004; Stahly 2007; Childs and Zavorotko 2009). There are still no drug forms 
on a market officially denoted as cocrystals, however there are new patents and patent 
applications (Almarsson et al. 2012), for instance,  WO2011067571 (2011)  of Astra 
Zeneca that claims cocrystals of the investigational drug candidate {1S- [1α, 2α, 3β (l,S* 
,2R*), 5β]} -3 -(7 -{[ 2 -( 3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-l,2,3-
triazolo[4,5-d]pyrimidin -3-yl)-5-(2-hydroxyethoxy)cyclopentane-l,2-diol, with a number 
of carboxylic acids. In spite of this, the opportunities the cocrystals can offer, such as the 
possibility to obtain additional multicomponent solid forms of weakly and non-ionisable 
molecules with improved pharmaceutical properties (e.g., solubility, dissolution rate, 
physical and chemical stability, and hygroscopicity) can be of high practical importance. 
Moreover, like salts, cocrystals can be used for the drug purification purposes (Bond et al. 
2012). 
The main difference between cocrystals and salts is the location of the proton between 
acid and base (Fig. 3). There is a common opinion that the salt will be formed by an acid 
and a base when the difference ΔpKa between (pKa)base  and (pKa)acid is larger than 2 
(known as the “rule of 2”). 
This criterion is traditionally used by drug development chemists as a cut-off rule to 
select the list of appropriate counterions for salt formation. In several studies, however, the 
crystal structures of salts and cocrystals with the number of coformers such that the 
difference pKa varied between –9 and + 9 have been compared. It has been noticed that 
in some cases the location of the proton in the solid is affected not only by ΔpKa, but also 
by the temperature and crystalline environment (Childs et al. 2007; Childs and Zavorotko 
2009). These studies demonstrate that it is not easy to make a division between salts and 
cocrystal by using only one criterion, such as the value of ΔpKa (Figure 4). In addition, 
the “rule of 2” does not predict the form, crystalline or amorphous, in which the salt of an 
acid and a base with ΔpKa > 2 will be obtained. This is the reason of why the concept of 
salt-cocrystal continuum has been introduced (Stahly 2007; Childs et al. 2007; Childs and 
Zavorotko 2009). According to this concept, the two classes are considered to belong to a 
single class of the salt-cocrystal continuum, in which pure salts and cocrystals are located 
at opposite edges. This implies that the “rule of 2” can be used only as an approximate 
dividing criterion when choosing an appropriate nomenclature, but not as an unconditional 
cutting-off criterion for choosing the components that might form a multi-component 
compound with a given drug candidate (Stahly 2007; Childs et al. 2007; Childs and 
Zavorotko 2009). It has been demonstrated that cocrystals, similarly to salts, can have 
considerably higher solubility than the neat drug substances, which is of prominent 
advantage for the drugs of BSC class II. 
  
 
 
22 
 
Figure 3 Salt-cocrystal continuum. 
2.2 Solid-state form screening approaches 
A very convenient, generic scheme for polymorph screening has been introduced by 
(Stahly 2007). This scheme can be extended to screening of all solid forms independently 
of such factors as the volumetric scale and total number of the samples, methods of 
crystallization and analysis, and the main target. The extended scheme is shown in Figure 
4 and its detailed description is presented in the following subsections. 
2.2.1 Characterization of materials in solid form screenings 
The goal of the initial characterization of the material (step 1 in Figure 4) is to obtain basic 
knowledge of solid-state properties of the material that will be used in further steps of the 
screening. The starting material should be comprehensively characterized by using 
standard analytical techniques, such as powder x-ray diffraction (PXRD), differential 
scanning calorimetry (DSC), thermogravimetry (TGA), thermomicroscopy, infrared (IR) 
spectroscopy, Raman spectroscopy, solid state magnetic resonance (ssNMR) 
spectroscopy, and gravimetric vapor sorption (GVS) analysis. It is also important to 
develop a method for appropriate verification of the chemical integrity of each new solid. 
This method can be based on solution NMR or high performance liquid chromatography 
(HPLC). Already during this characterization, an indication of possible polymorph or 
hydrate formation can be revealed (Cui and Yao 2008; Llinas and Goodman 2008; Brittain 
2009; Tian et al. 2010). The obtained data will then be used in further characterization 
steps of the screening procedure. The same analytical techniques will be used also for the 
qualitative phase analysis of the samples (step 4, Fig.4) and characterization of each new 
form (step 6, Fig.4). 
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Since in majority of screenings the crystallization step is involved for generation of 
solid samples, it is necessary to evaluate the solubility of the material in the scope of 
organic solvents for both single component and multi-component screenings.  
 
Figure 4 Schematic presentation of solid-form screening and selection. Modified from (Stahly 
2007). 
The technique might be chosen depending on the amount of the starting material available 
for the solubility assessment, for instance the well-plate technique, shake flask methods 
and gravimetrical methods can be used. The knowledge of the solubility in organic solvent 
is obligatory to establish the set of solvents for polymorph, solvate, salt or cocrystal 
screenings. It is also valuable to perform the solid state analysis of all solids remained in 
the result of the solubility analysis, and some new forms especially solvates might be 
discovered at this step (Byrn 1999; Alleso et al. 2008; Aaltonen et al. 2009; Brittain 2009; 
Bernstein 2011). 
It is assumed that if the screening is performed for the multi-component solid forms 
the same procedure should be performed, if not done previously, for the other starting 
materials: acids or bases for salt screening and coformers for cocrystal screening if they 
are solids. Moreover, for the solvate, salt and cocrystal screenings, the NMR, HPLC and 
elementary analysis are valuable to reveal the stoichiometry of the components in the 
crystal. Also the coupling of TGA analysis with head space mass spectroscopy (TGA/MS) 
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is very useful for evaluation of stoichiometry and stability of the solvates and 
hydrochlorides. 
Analysis of the single-crystal structure of the starting material and all the new obtained 
forms is of particular importance, since this structure explicitly reveals the conformations 
and packing configurations of the molecules in the crystal including possible hydrogen 
bonding schemes. In order to verify that the single crystal is the representative of the bulk, 
the PXRD pattern can be calculated for the single-crystal data and then compared with the 
experimentally obtained pattern of the bulk material. The information about the crystal 
packing is very important, since it can be used in the steps of selection of the most 
probable guest molecules that will form multi-component salts and cocrystals with the 
drug candidate molecule (Bernstein 2011). This will be considered in more detail in the 
following subsections.  
2.2.2 Generation of solid forms 
Single-component polymorphism and solvatomorphism screening 
 
The approaches used in different laboratories for characterization of starting materials and 
obtained solid-state forms are more or less similar, but the methods of the solid sample 
generation can differ significantly (Hilfiker et al. 2006; Bernstein 2011;). In the majority 
of polymorph screenings, new solid-state forms are generated by crystallization from a 
diverse set of organic solvents, using different temperature profiles and concentrations 
(Stahly 2007). Hence, in spite of the fact that solvates are multi-component forms, their 
screening is convenient to consider in the same scope with screening of single-component 
compounds.  
The crystallization techniques that do not use solvents are also utilized (Hilfiker et al. 
2006; Hilfiker (ed.) 2006; Bernstein 2011;). These techniques include treatment of the 
starting material under specific thermodynamic conditions, aging in various vapors, and 
mechanical processing.  
Due to a limited amount of substance available at the early discovery phase, most 
screening methodologies were adapted for using small-scale crystallization volumes and 
miniaturized-sample analysis techniques (Morissette et al. 2004; Stahly 2007; Bernstein 
2011). As a result, in all these approaches, the crystallization conditions significantly 
differ from those used in ordinary organic synthesis processes. As a rule, they do not 
include molecular synthesis at all. The small-volume approaches have a tendency to 
produce metastable and amorphous forms, as well as the mixtures of them. Because of this 
the most stable form can remain undiscovered. Moreover, it should be emphasized that the 
first small-volume screening for polymorphs and solvates does not give a control over the 
manufacturing of these forms at bigger amounts of the material. Consequently, there is a 
practical need for development of cost-effective methods for evaluation of polymorphism 
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and solvatomorphism tendency. These methods must serve the discovery of the most 
stable solid form at ambient conditions. 
Generation of solid forms of multi-component compounds: salts and cocrystals 
 
The progress from single-component screening to multi-component screening leads to 
emerging of additional challenges. In this case an additional step 2 that precedes sample 
generation (step 3, Fig. 4) must be used. In this step, a set of counterions and coformers 
shall be considered in view of formation of salts and cocrystals, respectively. It is 
recommended to use acids and bases as well as coformers that are proved to be safe for 
human (Stahl 2002). Considering the salt-cocrystal continuum concept, it is beneficial to 
choose the substances with various values of pKa and having diverse functionalities. It has 
been recently suggested that possible multi-component compounds can be theoretically 
predicted on the basis of supramolecular considerations. This topic will be separately 
reviewed in the upcoming sections (see section 2.3).  
After the substances are selected for the screening and characterized, as described in 
section 2.2.1, the generation of solid-state forms can be started. According to numerous 
recent publications, there are no substantial differences in the approaches used for salt and 
cocrystal generation. Since both these approaches differ from the polymorph and solvate 
screening, care must be taken to prevent premature crystallization of one of the 
components in a pure form. This crystallization does not lead to complex or salt 
formation. There are several techniques used in multi-component screening for sample 
generation: (1) slow evaporation, (2) mechanochemical synthesis by cogrinding, (3) 
reaction cocrystallization, (4) slurry conversion, (5) high throughput (HT) screening, (6) 
comelting, and (7) cooling. The occurrence frequencies of these techniques in the 
literature are distributed as shown in Figure 5 (Sheikh et al. 2009).  
All solvent based approaches, which are in the list, require selecting the best solvent or 
solvent mixture for the components which would result in the multi-component crystalline 
form of interest. In the slow evaporation technique the idea is to dissolve both components 
in solvent and let the solvent slowly evaporate and lead to supersaturation and subsequent 
crystallization.  
The solvent or solvent mixture should be chosen by using the ternary phase diagram of 
the components and the solvent (Chiarella et al. 2007), since the diagram describes the 
three phase behavior of a system. In the slow evaporation, the pure cocrystal or salt will be 
successfully crystallized, if the solubilities of both components are close to each other. 
The ternary phase diagrams (Figure 6) depict the regions where the certain solid phase is 
in equilibrium with the solution: region 1 – all components are dissolved; region 2 – the 
component C is in solid form; in the region 3 – the cocrystal or salt is in equilibrium with 
solution; in the region 4 – the component N is in solid form; and in the regions 5 and 6 
two solid phases are in equilibrium with solution: the cocrystal or salt and, 
correspondingly C and N. The points a and a´ are the solubilities of C in methanol and 
water, respectively; and points b and b´- of component N in methanol and water. In the 
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Figure 6 the dashed straight line represents the drying line of the solvent upon 
evaporation. Methanol is chosen as a solvent for slow evaporation since the solubility of 
both components is similar (points a and b in the Figure 6 left). In this case the drying line 
of equimolar solution of C and N is within the stability region of the cocrystal (region 3,  
13 %
40 %
7 %
7 %
7 %
3 %
23 %
3% HT screening 
7% Comelting
7% Slurry conversion
7% Reaction crystallisation
40% Slow evaporation
13% Cooling
23% Grinding
 
Figure 5 The cocrystal screening techniques occurrence in the literature, adopted from  
( Sheikh et a. 2009). 
 
Figure 6 The cross section at T=25ºC of the ternary phase diagrams of cinnamic acid and 
nicotine amide with methanol (on the left) and with water (on the right). 
Figure 5 left) and it will crystallize in pure form. In the contrast, if the water would be 
used the drying line first meet the region where the component C is stable and it will be 
firstly obtained in solid form. Thus the resulting product will be the C and the cocrystal or 
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salt. Since the C will be crystallized first it is not guaranteed that the crystallization of the 
cocrystal will take place by kinetic reasons. 
For the reaction crystallization method water might be a better choice. The saturated 
solution of the component N can be prepared (see b´– the composition of saturated solid 
solution) and the component C should be added in the solid form (along with dotted line 
starting from b´ towards the C-corner in the diagram) until the crystallization of salt or 
cocrystal occurs (in the region 3 when the concentration of C will be within the end point 
of arrow). Therefore, in the reaction crystallization technique it is essential for a successful 
multi-component synthesis to select a solvent that gives a high solubility for the drug 
molecule and a low solubility for the salt or the cocrystal (Rodríguez-Hornedo et al. 2006; 
Jayasankar et al. 2009; Chadwick et al. 2009; Collman et al. 2013). The solution of the 
drug molecule can be prepared near the saturation point. Then, the guest substance should 
be added in a solid form until the desired salt or cocrystal will be crystallized from the 
solution.  
In the slurry conversion synthesis the solubility should be taken into account also, 
since the slurry of both components should be prepared so that they will not be dissolved. 
This can be achieved by lyophilization or anti-solvent addition or cooling (Takata et al.  
2008; Bučar  et al.  2010).  
The automated HT screening approaches, that include crystallization in tiny micro-
wells (Kumar et al.  2007; Kojima et al.  2010) and the use of microfluidic platforms 
(Thorson et al. 2011; Goyal et al.  2012), have become very popular in the last years. In 
these approaches, in order to increase the chance of finding “hits”, each compound is 
exposed to a diverse set of solvents, crystallization conditions, and techniques. In such 
screens, only small amounts of the material are generated and, therefore, a detailed 
characterization and understanding of the nature of the discovered form is impossible. 
Consequently, an additional scaling–up step is required to produce larger volumes of the 
compounds. Often, the scaling-up step fails to yield the same compound, in which case the 
findings of the first HT step have no practical value (Stahly 2007; Collman et al. 2013). 
Successful obtaining of salts and cocrystals by using mechanochemistry methods, (2), 
has been recently reported in many scientific publications (Braga and Gepioni 2005; 
Friščić 2010; James et al. 2012). The success can be explained by the ternary phase 
diagrams (Chiarella et al. 2007). Since the dry solid components are mechanically grinded 
(with or without a very small drop of a solvent), the synthesis takes place in the close 
proximity of the stability region of the cocrystal or salt in the phase diagram. 
Consequently, the role of solubility of the components in the solvent is minimized. It 
should still not be underestimated. The method is ecologically sustainable, but it is limited 
from the industrial scale production point of view. Recently, however, an extrusion 
technique has been reported to give very promising results for scaling up the process 
(Medina et al. 2010).  
The comelting approach, on the other hand, allows one to completely get rid of using 
solvents. In this case, it is enough to consider only the binary phase diagram. To 
accomplish the process, one has to mix the component in the stoichiometric proportion, 
heat the mixture to obtain the melt, let the system to reach equilibrium, and slowly cool 
the melt to obtain the salt or the cocrystal of interest. This approach, combined with 
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optical microscopy, was applied by Kofler already in 1943. Also Raman microscopy can 
be used for observation of crystallization dynamics when using this method (Davis et al. 
2004; Berry et al. 2008). A serious limitation of the method is that it can be applied only if 
there is no chemical decomposition of the components during the melting. 
The supercritical fluid technology (SCFT) has experienced a strong growth in the past 
decade, particularly in the field of materials processing, being more and more proposed as 
an alternative to many conventional solvent-based processes (Padrela et al. 2009, 2010). 
Using this alternative technology a group of scientists (Padrela et al. 2009, 2010) have 
obtained the cocrystals of indomethacin, theophylline, caffeine, sulfamethazine, aspirin 
and carbamazepin with saccharin.  
The important pharmaceutical properties of all new solid-state forms obtained in the 
screening should be investigated and the best form should be selected for the development 
of the new drug candidate (steps (7) and (8) in Figure 3). This procedure will be 
considered in detail in section 2.4. 
In the present study two most popular methods, the slow evaporation and the 
mechanochemistry synthesis, are compared in order to achieve practical understanding of 
the applicability of both techniques for industry. 
2.3 Supramolecular chemistry and crystal engineering for 
selection of potential counterions and coformers  
 
In order to select an appropriate set of counterions and coformers for the salt or cocrystal 
formation, one can use the methods of crystal engineering and supramolecular chemistry. 
The term ‘crystal engineering’ has been proposed by Schmidt in 1971 (Schmidt 1971) in 
connection with the photodimerisation reactions in crystalline cinnamic acids. Since then, 
crystal engineering has become a well established branch of science that in fact includes 
also some aspects of the solid-state supramolecular chemistry. Perhaps one of the most 
accurate definitions, proposed by Gautam Radhakrishna Desiraju in 1988, defines crystal 
engineering as "the understanding of intermolecular interactions in the context of crystal 
packing and the utilization of such understanding in the design of new solids with desired 
physical and chemical properties" (Desiraju 2007; 2009). 
The main interactions responsible for the salt formation are of ionic nature. There is a 
common opinion that the base and acid will form a salt if the difference between their pKa 
values will be larger than 2. Thus, if the value of ΔpKa of a drug-candidate molecule is 
calculated or determined experimentally, a set of appropriate acids or bases can be formed 
by considering their pKa values. This approach, however, does not guarantee that all salts 
will be obtained in a crystalline form (Trivedi et al. 2003). Moreover, if the drug molecule 
contains several protonation sites, it is not always clear which site will be protonated. 
Finally, as it was described in subsection 2.1.4, in those cases when the 0 <ΔpKa<2 there 
is no guarantee that there will be proton transfer in solid state. Thus the guidelines 
described in the following paragraph are similarly applicable to salts (Mei and Wolf 2004; 
Ong 2011). 
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In non-ionic crystals, the crystallization is guided by less predictable and weaker 
interactions, such as hydrogen bonding, π-π bonding of aromatic rings, van-der-Waals 
bonding and halogen bonds. For favored hydrogen bond arrangements in non-ionic 
crystals, certain guiding principles (based on scrupulous analysis of hydrogen bonds and 
packing motifs) have been developed by Donohue 1959 and Etter 1990 (Byrn 1999) These 
principles include the following guiding rules: (a) all acidic hydrogens available in a 
molecule will be used in hydrogen bonding in the crystal structure of the new compound, 
(b) intramolecular hydrogen bonds that form a six-membered ring will occur in preference 
to intermolecular hydrogen bonds; (c) the best proton donors and acceptors remaining 
after formation of intramolecular hydrogen bonds form intermolecular hydrogen bonds to 
one another; (d) all good acceptors will be used in hydrogen bonding when there are 
available hydrogen-bond donors, and (e) the best hydrogen-bond donor and the best 
hydrogen-bond acceptor will preferentially form hydrogen bonds to one another. 
Additional rules for specific classes of functional groups have been also determined. Etter 
also mentioned various reasons that can make these principles inapplicable (Etter 1990; 
1991). These reasons include the presence of multiple competitive hydrogen-bond sites, 
conformational freedom, steric hindrances, and competing dipolar or ionic forces.  
The Cambridge Structure Database that contains empirical structures of a half a 
million of organic crystals gives an additional opportunity for searching for the most 
common functional groups and the information on how they can be connected in a 
molecular association (Chisholm et al. 2006; Laszlo 2009). These types of non-covalent 
connections between functional groups are supramolecular synthons that are analogous to 
the covalent bonds in synthetic chemistry (Vishweshwar et al. 2006). Therefore the guest 
molecules having the complementary favorable functional groups can be chosen as the 
most probable candidates for screening (Laszlo 2009). The example of the supramolecular 
considerations for selecting the most probable host-guest pairs is described below. For 
instance, according to (Vishweshwar et al. 2006), carboxylic acid groups exist in 30 of 
100 top-selling prescription drugs in USA and they are the most frequently studied 
functional groups in supramolecular chemistry. Their hydrogen-bond donor and acceptor 
sites make a supramolecular homosynthon I (see Figure 7) favorable. However, formation 
of this synthon is unlikely in competitive situations. A CSD study on carboxyl donors 
indicated that carboxylic acid–pyridine interactions through O-H…N hydrogen bonding, 
synthon II, is more favored than synthon I (Vishweshwar et al. 2006). Indeed, the synthon 
II is a reliable supramolecular heterosynthon that has been widely exploited in crystal 
engineering. Furthermore, the synthon II is energetically favored over the synthon I and 
the acid-amide supramolecular heterosynthon IV is favored over synthons I and III 
(Vishweshwar et al. 2006).  These examples show those types of considerations that 
should be applied in the design of co-crystals, since the use of the robust supramolecular 
heterosynthons are probably the most reliable and rational route to obtaining co-crystals 
(Aakeröy and Salmon 2005; Miroshnyk et al. 2009; Delori et al.2013). Moreover, the 
ionic synthones could be used for design of salts (Mei and Wolf 2004; Ong 2011). 
It is not clear, however, whether these simple considerations can be applied if the 
functional groups of the drug candidate contain several good acceptors and competitive 
donors. Analysis of the last-decade publications shows that very often, formation of a co-
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crystal is difficult, if not impossible, to predict, especially when the molecules have 
complicated structures (Desigaju 2012). Co-crystallization of cis-itraconazole with a series 
of 1,4-dicarboxylic acids can be mentioned as an example. 
 
Figure 7 Examples of the most popular synthons. Adopted from (Vishweshwar et al. 2006). 
It is remarkable that the interaction between succinic acid and the strongest basic group of 
itraconazole (piperazine moiety) was not present in the co-crystal structure (Remenar et al. 
2003; Blagden et al. 2007). Instead, the COOH-group of succinic acid was found to be 
connected to a 1,2,4-triazole group, which is not an expected result.  
Crystal engineering and supramolecular synthesis of complex molecules are currently 
very active areas of theoretical and experimental investigations. Moreover, the reversible 
molecular interactions that hold together the API and the co-crystal former (or co-former) 
have the same nature (i.e., H bond, Van der Waals interaction, metal coordination) as 
those that take place between the API and its biological target. This makes the co-
crystallization a general approach on the pharmaceutical arena (Desigaju 2012).  
2.4 Selection based on evaluation of pharmaceutical properties 
The main goal in performing solid-state screening is to find a form that will have optimal 
properties in view of development of a new drug candidate (Stahly 2007; Byrn 2012). 
Therefore, the properties of the forms found in the screening must be carefully studied and 
compared with each other. The most critical properties that must be improved should be 
selected as a main target to tackle (Gould 1986; Newman et al. 2010). This can be done on 
the basis of the in-silico predicted physical and chemical properties of the new drug 
candidate and the initial characterization results of the first solid batches of the material. 
The new drug candidate may have poor solubility and bioavailability, chemical and/or 
physical stability and crystallinity or high hygroscopicity (Byrn 2012). Table 2 shows (a) a 
list of important solid-state properties to be addressed in the research, (b) the associated 
characterization methods, and (c) a description of the properties of an ideal candidate for 
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the development of an oral dosage form. The table can be used as a guide for selection of 
the most promising solid-state forms for new drugs.  
Table 2. Properties of the solid-state forms for selection of the optimal one. 
Property Method Ideal properties for development 
of oral dosage form 
Solubility Shake flask method. Solubility 
in biorelevant media or in buffer 
solution 
Proposed dose should be soluble in 250 ml 
biorelevant media in pH range 1.2-7 
Dissolution rate IDR using Wood’s apparatus in 
biorelevant media or buffer 
solution 
IDR > 1mg/cm2/min in pH range 1.2-7 
Bioavailability 
 
 
 
Pharmacokinetic study on 
animals (rat, dog, monkey). 
Measurement of AUC or Cmax, 
depending on the product target. 
Bioequivalent or better than i. v.  solution. 
Crystallinity PXRD Crystalline. The absence of amorphous content 
Melting point DSC, thermomicroscopy Melting point preferably >100ºC 
Hygroscopicity GVS Not hygroscopic in the RH range 10-90%. If 
hygroscopic, than controllable formation of 
stable hydrate 
Physical stability GVS, DSC, non-ambient 
PXRD, solid-state spectroscopy 
(Raman, IR, NIR, Teraherz, 
NMR) after stressed conditions 
at 60ºC/100% RH for 2 weeks 
No phase transitions induced by moisture or 
temperature changes.  
No disproportionation of the salt or cocrystal.  
Polymorphism Batch-to-batch PXRD, DSC, 
recrystallization from 4-5 
solvents, grinding experiments 
No or low polymorphism tendency 
Chemical stability Degradation studies performed 
under stressed conditions for 2 
weeks 
Stable in the solid form under stressed 
conditions 
Crystallization 
process  
Scaling-up of crystallization. 
 Measuring of the yield.  
Scalable process with high yield using Class 3 
solvents 
Solubility/dissolution rate and bioavailability 
The need for enhancement of aqueous solubility of new drug candidates is commonly 
recognized as a crucial step in the pharmaceutical sciences. In our studies, the solubility 
enhancement is considered as one of the most important priority factors for the form 
selection. The solubility and the dissolution rate of the drug can be tailored by prudent 
selection of the salt. For example, in this way, the solubility can be enhanced by two 
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orders of magnitude (Stahl 2002; Serajuddin 2007) and still, if necessary, it can be 
significantly reduced by selecting hydrophobic, fatty or bulky counterions (e.g. laurate, 
pamoate, resinate) (Aungst and Hussain 1992). The solubility reduction can be used in the 
controlled and sustain release development.  
The solubility and dissolution rate of very weak bases or acids, as well as of non-ionic 
molecules, can also be enhanced by formation of cocrystals (Remenar et al.  2003; 
McNamara et al.  2006; Wassvik et al. 2006; Stahly 2007; Bak  et al. 2008; Good et al.  
2009; Babu and Nangia 2011; Gao and Zang 2011; Smith et al. 2011; Stephenson et al.  
2011; Elder et al. 2012; Chadha et al. 2012; Weyna et al. 2012; Xu et al. 2012; Brittain 
2013; Steed 2013; Thakuria et al.  2013). To my knowledge, cocrystals have not been 
used to reduce drug solubility. However, according to (Elder et al. 2012), formation of 
cocrystals can also lead to a solubility reduction.  
The solubility of thermodynamically less stable polymorphs is usually the same or 
higher than that of more stable polymorphs (Llinas 2007). However, the solubility 
enhancement through crystallization of different polymorphic forms is not as high as by 
means of formation of salts. A comprehensive review on the degree of solubility 
enhancement by high-energy polymorphs is given in (Pudipeddi and  Serajuddin 2005). 
According to this paper, less than 5 fold enhancement was achieved in the majority of 
cases, with an exception for  premafloxacin (23 folds). The reason for the limited spread in 
the solubility ratios can be in a rather small energy difference of the molecular-crystal 
modifications that often results from a packing or a conformational difference (Pudipeddi 
and  Serajuddin 2005). 
As a rule, formation of pharmaceutically acceptable solvates gives a higher solubility 
enhancement, 10-15 folds. Solvates, however, have a propensity to gradually loose the 
solvent of crystallization, which makes them less attractive in view of practical 
applications. On the other hand, formation of anhydrates instead of hydrates, if they can be 
made stable at normal conditions, is always of high practical interest (Pudipeddi and  
Serajuddin 2005). The hydrates, being more stable in water than anhydrates, are known to 
have a lower aqueous solubility (Grant 1990; Pudipeddi and  Serajuddin 2005). 
The enhancement of the solubility and the dissolution rate should be ensured to 
translate into an increased in-vivo exposure, since there are risks of the salt 
disproportionation and a common-ion effect. As an example, an increased bioavalability 
of a low soluble drug candidate was achieved by cocrystal formation with saccharine (Bak  
et al. 2008). 
Hygroscopicity 
Salts with high solubility have been noticed to show also a high hygroscopicity, which can 
be an issue for salts of strong acidic (particularly di-HCl) and basic counter ions, such as 
Na and K. High hygroscopicity, however, can induce problems in the pharmaceutical 
processing and storage of both the API and the drug product (Morris et al., 1994). This 
problem should definitely be addressed in the future pharmaceutical research.  
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Melting point 
Melting point is an important characteristic of all solids. In view of pharmaceutics, high 
melting points are usually considered to be beneficial. However, they can contribute to 
poor solubility and be as problematic as low melting points that are known to hinder the 
processing, drying, and stability of the material.  For salts, the enhancement of solubility is 
obtained primarily due to the ionization effect. For cocrystals and polymorphs, on the 
other hand, the role of the crystalline lattice energy and, consequently, the melting point 
are of particular importance. The correlation between the solubility and the melting points 
of the cocrystals is currently a subject of thorough investigations (Chu and Yalkowsky 
2009; Elder and Holm 2012). In (Stanton and Bak 2008), for example, a good correlation 
between the melting points of the coformer and the cocrystal has been found, which 
provided the possibility to tailor the properties of the cocrystal by selection of the 
coformer. Simultaneously, the authors revealed less correlation between the melting point 
and the solubility of the cocrystals. Obviously the melting point is not the only factor 
affecting the solubility. For instance the hydrophilicity of the coformer can also play an 
important role (Elder et al. 2012). 
Polymorphism and solvatomorphism tendency 
As already mentioned in subsection 2.1.3, both single- and multi-component substances 
can exhibit polymorphism. A comprehensive statistical analysis of empirical data on 
polymorphism tendency is presented in (Stahly 2007). The data in question is based on the 
245 polymorph screens conducted by SSCI. The analysis shows that single compounds are 
more frequently polymorphic than salts (55% compared to 39%), but the salts more 
frequently exist as hydrates (48% compared to 30%). This is an expected result based on 
the known affinity of water to bind to ionic sites. Many organic molecules are able to 
crystallize into many polymorphic forms, although there are examples of molecules that 
do not have this ability, for instance ibuprofen. The ability of the organic substances to 
crystallize in different forms cannot usually be predicted. Therefore, it must be found 
through experiments (Stahly 2007). Because of the lack of a representative amount of 
experimental data, analytical study of the polymorphism tendency of cocrystals is 
impossible at the moment and therefore it must be conducted in the future. The importance 
of this research is discussed in (Eddleston et al. 2013), where the authors study the 
polymorphism tendency of a phenazine:mesaconic acid (1:1) cocrystal. Discovery of three 
polymorphs, including one hydrate and one DMSO solvate, of the cocrystal in the 
screening is reported. 
The propensity for the polymorphism can be evaluated using a small amount of 
material, say, 100-200 mg. Therefore, to enable the best form selection for the 
development, the polymorphism tendency evaluation should be done in the later stages of 
drug discovery. It is important to emphasize, that at these stages, it is far more important 
to discover the most stable form of the new drug candidate than to discover its all possible 
polymorphic forms. Focusing the screening on finding this most stable form can ensure 
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the scalability of the crystallization process and enable the proper form selection for the 
development (Stahly 2007). 
Physical stability 
As mentioned above, the selected solid-state form must show an acceptable physical 
stability both at the crystallization conditions and at normal laboratory conditions in order 
to enable the scalability of the crystallization process and the long-term shelf-life of the 
API and the oral drug form. The physical stability for different polymorphs of a compound 
is connected to such thermodynamic properties as monotropicity and enantiotropicity 
which therefore must also be determined (Stahly 2007, Newman et al. 2010; Byrn and 
Henck 2012). Furthermore, the physical stability of the discovered solvates, including 
hydrates, should be tested at stressed conditions (Stahly 2007; Newman et al. 2010; Byrn 
and Henck 2012), and finally, the disproportionation tendency of the salts or cocrystals, if 
such are discovered, must be evaluated. The propensity for the disproportionation has been 
reported for hydrochlorides and other salts of very weak bases. It is indeed a much 
undesired property that can lead to a significant reduction of the solubility and the 
dissolution rate (Guerrieri and Taylor 2009; Stephenson et al. 2011).  
Crystallinity and crystallization process  
The main advantage of the crystalline solid-state forms over the amorphous ones is that 
the former can have high solubility and simultaneously be more stable both physically and 
chemically. Because of this, the crystallinity of the polymorphs, solvates, salts or 
cocrystals must be controlled and only the crystalline forms must be selected for further 
development, unless the amorphous form is what is desired for some other reason. 
 
The formation of a salt or a cocrystal can often help to crystallize a substance that is 
difficult or impossible to crystallize otherwise (Wouters and Quéré 2012). Furthermore, 
the formation of salts and cocrystals has been shown to lead to an effective purification of 
the sample from synthesis impurities and from stereomers and enantiomers (His et al. 
2012; Billot et al. 2013). Naturally, the forms that can enable both crystallization and 
purification are of great interest for medicinal chemists. 
Chemical stability 
New solid-state forms of a given drug candidate must be demonstrated to have at least the 
same chemical stability as the neat material. Many drug molecules, however, are 
susceptible to decompose, which can complicate or even stop the drug development. 
Forming of a salt can be a very efficient way to enhance the chemical stability of the drug 
against the decomposition (Stahl 2002). Also cocrystals are reported to offer this 
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possibility. As an example, a 1:1 cocrystal of nitrofurantoin-4-hydroxybenzoic acid has 
been shown to have a superior photostability compared to the neat nitrofurantoin (Vangala 
et al. 2011).  
Mechanical properties  
Different solid-state forms due to different internal as well as external structureswill have 
different mechanical properties, such as flowability and compressibility. Consequently 
they are of importance for the manufacturing process of the drug product. The scope of the 
mechanical properties is important to consider at the later development stages of the drug 
development process and they are excluded from the scope of the present study.  
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3 Aims of the Study 
The aim of this study was to develop means for expanding diversity of developable solid-
state forms of weakly basic drug molecules to be applied in pharmaceutical sciences. 
 
The specific aims of the study were: 
 
(1) To find the most stable form of hydrochloride salt of a new drug candidate in order 
to enable the effective pharmaceutical development of the oral dosage form. 
 
(2) To assess the feasibility of molecular modeling tools for coformer selection. 
 
(3) To develop an effective screening approach that can be used in industry for salt and 
cocrystal screening. 
 
(4) To conduct the comparative study of the most critical pharmaceutical properties of 
new salts and cocrystals of itraconazole. 
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4 Experimental 
Detailed description of the utilized experimental approaches can be found in the original 
publications (I-IV). 
4.1 Materials 
The basic drug substance used in the Publication I was a new drug candidate ORM10921, 
IUPAC name [1R*,12bR*)-(-)-1,3,4,6,7,12b-Hexahydro-1-methoxymethyl-1-methyl-
2Hbenzofuro [2,3-a]quinolizine] (Figure 8). Its hydrochloric salt were synthesized by 
Orion Pharma, Finland. The absolute configuration was assigned by optical rotation and 
later by single crystal X-ray diffraction. The optical purity of the material was >97%. 
 
Figure 8 Chemical structure of the investigational drug, ORM10921. 
The weak base used in the rest of Publications (II-IV) was itraconazole (ITZ, purity 99.7% 
see structure in figure 9). The material was purchased from Apotecnia S.A. 
 
Figure 9 Chemical structure of itraconazole. 
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Dicarboxylic acids (C2-C10) used in Publications II, III and IV, which are oxalic acid 
anhydrate, malonic, succinic, glutaric, adipic, pimelic, suberic, azelaic, and sebatic acids 
(ACS reagent > 99%) (Figure 10) was purchased from Sigma-Aldrich. Concentrated 37% 
hydrochloric acid water solution (Sigma-Aldrich Co.) and HCl gas (Aga Linde Group, 
purity 99.995%) were used as received. The analytical grade solvents used for the studies 
were obtained from the commercial sources. 
 
 
Figure 10 Chemical structure of the dicarboxylic acid of growing carbon chain length (C2-C10) 
used in the study. Oxalic (C2), malonic (C3), succinic (C4), glutaric (C5), adipic 
(C6), pimelic (C7), suberic (C8), azelaic (C9) and sebacic (C10) acids. 
4.2 Preparation of new solid state forms 
4.2.1 Hydrochloric salts of ORM10921 
The final crystallization of the synthesis process consisted of dissolving of the ORM10921 
free base in ethyl acetate or a mixture of ethyl acetate with another solvent. Then 10% 
  
 
 
39 
solution of HCl in ethyl acetate was slowly added with a constant stirring rate. After 
accomplishing the salt precipitation, the slurry was cooled in an ice bath for 3 h, filtered, 
and washed in ethyl acetate with subsequent drying in vacuum at elevated temperature.  
4.2.2 Hydrochloride salts of itraconazole 
Gas bubbling (Method A) 
Itraconazole was added to acetone. The anhydrous HCl gas was bubbled slowly into the 
mixture. After the hydrochloride salt was precipitated the final product was collected by 
ﬁltration, washed with acetone and dried in vacuum. 
Salting out from solution (Method B) 
Itraconazole was added to acetone. Then the concentrated (37%) water solution of HCl 
was added to the mixture. The slurry was heated to 50 ºC. The clear separation of 
transparent liquid was followed by precipitation of white flakes. The mixture was allowed 
to stabilize overnight at room temperature. Thereafter the product was collected by 
ﬁltration, washed with acetone and dried in vacuum. 
4.2.3 Cocrystals of itraconazole and dicarboxylic acids  
Mechanochemical synthesis by solvent assisted grinding 
The mechanochemical synthesis we used in the study proceeds as follows. The neat 
itraconazole and acids are weighted in desired ratios to obtain 1 g samples. The grinding 
experiments are performed using a planetary ball mill (Pulverisette 6, Fritsch GmbH, 
Germany) in a stainless steel grinding bowl of 80-mL volume with four grinding balls. 
The synthesis is assisted with acetone (200 µL). The resulting powder was removed from 
the bowl into a glass vial and dried in vacuum. 
Slow evaporation 
Stock solutions of pure itraconazole in chloroform and a dicarboxylic acid in 
tertrahydrofuran (THF) and chloroform (CLF), respectively, were mixed in glass flask to 
obtain 1:1 and 2:1 molar mixtures of itraconazole and acid, correspondingly. An excess 
solvent was then added, if needed, to form a 1:1 (CLF:THF) volume ratio. The prepared 
solutions were heated with continuous stirring to ensure complete dissolution of the solids. 
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Thereafter, the bottles were sealed with a perforated film, through which the solvent 
slowly evaporated. After appearance of the first crystals, the film was removed to speed up 
the evaporation. The final drying, after the complete evaporation of the solvent, was 
performed in a vacuum oven. 
4.2.4 Growing of single crystals of studied forms 
A good quality single crystal of the ORM10 21 ∙HCl hemihydrate was selected from the 
1g batch (B6 in Publication I) crystallized by the described synthesis process where 
acetate/water (90/10 v/v) was used as the crystallization solvent. 
Single crystals of the neat itraconazole 
The single crystals of itraconazole were obtained by recrystallization of commercial 
itraconazole in dimethyl sulfoxide. In a clean and dry test tube (10 mL) itraconazole (100 
mg) was taken and added dimethyl sulfoxide (2.0 mL) and the suspension was heated until 
a clear solution was obtained. The resulted solution was allowed to attain room 
temperature. The crystalline precipitate appeared after 12 h and was collected directly 
from the test tube. 
Itraconazole-succinic acid (2:1) cocrystal 
To a mixture of itraconazole (200 mg, 0.283 mmol) and succinic acid (16.8 mg, 0.142 
mmol) taken in a 25 mL r.b. flask, a mixture of solvents (15 mL) consisting of 1,2-
dichloroethane, ethyl acetate and 1,4- dioxane (10/2/1 v/v/v) was added. The resulted 
mixture was heated until a clear solution was formed. The solution was allowed to attain 
room temperature and after 8 h the crystalline solid was filtered. 
4.3 Analytical methods 
4.3.1 Solid-state characterization and pharmaceutical properties of new 
forms 
Qualitative phase analysis by x-ray powder diffraction (PXRD) 
For qualitative phase analysis the conventional X-ray powder diffraction method was 
used. Philips X’Pert PRO multipurpose θ­θ diffractometer equipped with the RTMS (Real 
  
 
 
41 
Time Multiple Strip) detector. Filtered Kα radiation from Cu tube at 40 mA and 45 kV 
was used. The qualitative phase analysis was carried out by comparing the experimental 
PXRD patterns with patterns of known solid forms found from Cambridge Structure 
Database (CSD), Powder Diffraction File (PDF)/2 and PDF/4 of the International Centre 
for Diffraction Data® (ICDD) as well as by the manual comparison of patterns found in 
literature. 
Raman spectroscopy 
New forms were studied by Raman spectroscopy as a complementary characterization 
technique giving deeper insight into the structural changes caused by cocrystal formation 
on molecular level. Raman spectra were collected using a dispersive Raman microscopy 
(inVia, Renishaw) using a 785 nm diode laser, and 20-50x magnification objective lenses. 
Thermal analysis (DSC,TGA) 
The differential scanning calorimetry (DSC) and thermal gravimetrical analysis (TGA) 
were conducted as supporting methods for the solid-state characterization. Melting 
behavior was analyzed by differential scanning calorimeter (DSC821e, Mettler Toledo 
AG, Switzerland). The scans were performed, heating the sample from 25 to 240 ºC with a 
heating rate of 10 ºC/min in nitrogen atmosphere. Loss of weight was monitored with a 
thermobalance (TGA 851e, Mettler Toledo AG, Switzerland). Samples were analyzed at a 
heating rate of 10ºC/min under nitrogen purge. 
Hygroscopicity and moisture sorption-desorption isotherms (GVS) 
The moisture sorption-desorption isotherms were measured by the humidity and 
temperature controlled microbalance system, Dynamic Vapour Sorption (DVS 1, Surface 
Management Systems Ltd, United Kingdom). The moisture sorption-desorption behavior 
of the samples (~10 mg) was determined by continuously measuring the weight change of 
the samples with two successive cycles of relative humidity (RH), each one starting from 
0% to 90%-95% and backward to 0%, using 10% RH steps. After the experiments the 
qualitative phase analysis was performed by PXRD in order to detect possible phase 
transition caused by the high humidity. 
Intrinsic dissolution rate (IDR) 
IDR testing of all solid state forms of ITZ were performed using the dissolution device 
Sotax AT7 (Sotax AG, Switzerland) equipped with rotating disc (Wood’s apparatus). The 
solid powder was compressed in a die against a steel plate to yield a disk of known surface 
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area (0.5 cm
2
). Before and after the IDR measurements, the crystallinity and phase 
composition of the compacts was verified by PXRD. The dissolution studies (n=3) were 
carried out in 500 mL medium at pH 1.2 (hydrochloride acid buffer, Ph. Eur. 6.8) and 37 
ºC. For each time point, 1 mL of dissolution medium was collected during the experiments 
and replaced with 1 mL of fresh pre-warmed (37 ºC) medium. 
4.3.2 Structure elucidation and purity verification 
Nuclear magnetic resonance (NMR) 
The solid state NMR 13C CPMAS spectra were recorded on a Bruker AV400 
(spectrometer equipped with a 4 mm standard bore CPMAS probe head whose X channel 
was tuned to 100.62 MHz for 13C. The 13C CPMAS NMR was carried out for all samples 
under Hartmann–Hahn conditions with TPPM decoupling. The 13C CPMAS NMR 
chemical shifts are referenced to the C=O signal of glycine at 176.3 ppm and 15N 
CPMAS chemical shifts were referenced to the glycine signal at -345.25 ppm. 
The solution NMR spectra were collected on a Bruker Avance III 600 MHz equipped 
with 1.7 mm TCI inverse-cryoprobe with z-gradient. Experiments were conducted at 
temperature of 300 K. The verification of a proposed structure was accomplished by using 
1H, 13 C{H}, COSY, HSQC, HMBC and ROESY experiments. Proton and carbon 
chemical shifts were calibrated to TMS (δ=0.0) or residual DMSO-d6 signal (δC = 3 .52 
ppm). Acquired NMR data were processed by TopSpin 2.1 (Bruker, version 2.1), ACD 
1D, 2D Manager and ACD C13 Predictor (Advanced Chemistry Development, Inc., 
ACDLabs version 11.02) both Perch software (Perch Solutions Ltd., Version 2009.1 SA) 
High performance liquid chromatography (HPLC) 
The purity of ORM10 21 ∙HCl hemihydrate was determined by HPLC using Agilent 1100 
series (Agilent Technologies, Germany) chromatograph consisting of binary pump, a 
column compartment, a multi-wavelength detector UV-VIS, a well plate autosampler and 
a degasser. The separation of ORM10921 was achieved by using an XTerra MS C18, 250 
x 4.6 mm, 5 μm column at a flow rate 1.0 mL/min. The mobile phase during determination 
(λ= 250 nm) was acetonitrile and 10 mM ammonium bicarbonate water solution at pH  . 
Sample injection volumes of 10 µL were used for analysis. 
 
The itraconazole content of the samples from IDR and the purity of the solid state 
forms were determined by HPLC using an Agilent 1100 series (Agilent Technologies, 
Germany) chromatograph consisting of a binary pump, a column compartment, a multi-
wavelength detector, a well plate autosampler and a degasser. The separation of 
itraconazole was achieved by using a Gemini C18 column and a flow rate of 1 mL/min. 
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The mobile phase during determination (λ = 261 nm) consisted of acetonitrile and 0.1% 
trifluoroacetic acid pH 2.0. Sample injection volumes of 20 µL were used for analysis. 
Elemental analysis (EA) 
EA of the samples were performed by standard combustion method (Vario Micro cube 
Elementar Analysensysteme GmbH, Germany). Samples were fed automatically into a 
combustion zone. Combustion gases were sent to a catalytic post combustion zone and 
then to a reduction zone. The formed analyte gases N2, H2O, CO2 and SO2 carried by He 
gas were sequentially separated by a temperature programmable desorption (TPD) and 
quantitatively determined on a thermo-conductivity detector (TCD). 
X-ray single-crystal analysis 
Single-crystal diffraction analysis performed for the ORM10921 hydrochloride 
hemihydrate 
 
The single-crystal X-ray diffraction data were collected using a Bruker Nonius (1998) 
single crystal X-ray diffractometer. The cell refinement and data reduction were 
performed with DENZO and SCALEPACK software. The software to solve the structure 
was SHELX97 and to refine the structure SHELS97. 
 
Single-crystal diffraction analysis performed for the neat itraconazole and itraconazole-
succinic acid cocrystal 
 
Good quality plate-shaped crystals were subjected to the single crystal X-ray diffraction 
analysis. In order to examine the validity of the suggested disorder model (proved to be 
similar in all crystals), several single crystals were used for the structure analysis. The data 
collections were carried out both at -150.0 ± 0.1 and at 0.0 ± 0.1 ° (cooled by Oxford 
Cryostream) using Agilent Supernova dual wavelength diffractometer with two micro-
focus X-ray sources (Cu and Mo) of which multilayer optics monochromatized CuKα 
radiation was applied (λ = 1.54184 Å; 50 kV, 0.8 mA). The data acquisition (Atlas 
detector), reduction, multi-scan and analytical face-index based absorption corrections 
were all made by program CrysalisPro. The crystal structure was solved by ShelXS2 
implemented in program Olex2 (v 1.2 ) and refined on F2 by full matrix least squares 
techniques (ShelXL) using anisotropic displacement parameters for all non–hydrogen 
atoms. 
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5 Results and Discussion 
5.1 Polymorphism and solvatomorphism tendency evaluation of 
the hydrochloride salt of a new drug candidate, I 
ORM10921, a promising new drug candidate, has exhibited efficacy in rodent models 
predicting antipsychotic and antidepressant activity. This molecule is a weak base (pKa = 
7.4) that shows a low water solubility (7.5 μg/mL in phosphate buffer at pH = 7.4). To 
enhance the solubility of the ORM10921 base, a salt formation approach was employed, 
and a traditional hydrochloride (HCl) salt was synthesized. The main focus of the study 
reported in Publication I was on evaluation of the polymorphism and solvatomorphism 
tendency and stability of ORM10921∙HCl. 
5.1.1 Rational polymorphism screening approach based on the properties of 
the initial material, I 
According to the PXRD analysis (I, Fig. 4), the amorphous form was found to be a 
predominant solid phase for the initial three batches of the material. Moreover, the 
moisture-induced crystallization of this amorphous material was revealed at 55% RH. The 
crystallization was manifested by a sudden weight drop during the first moisture sorption 
cycle performed by GVS (I, Fig. 4A). The fact of crystallization was further verified by 
the PXRD pattern that exhibited sharp diffraction peaks and the absence of the amorphous 
halo (I, Fig. 4B). The TGA analysis of the sample after GVS revealed the 2:1 
stoichiometry of ORM10921∙HCl:H2O. Analyzing the obtained results, it has been 
hypothesized that, upon exposure to moisture, the amorphous material tends to crystallize 
into a more stable crystalline form, a hemihydrate (ORM10921 HCl∙1/2 H2O; hereafter 
denoted as HH). 
These observations confirmed well-known propensity of hydrochloride salts to form 
hydrates. Thus, we have chosen a rational approach for the fast initial polymorphism and 
solvatomorphism tendency evaluation tailored specially for this case. Our polymorphism 
screening approach is based on systematic examination of solid-state properties of 
subsequentially synthesized batches at the real-process scale. This approach is 
schematically presented in Figure 11. Briefly, physical characterization of each fresh batch 
of a new substance is performed by means of standard methods, such as PXRD, DSC and 
TGA. This characterization gives a feedback for optimization of the crystallization 
parameters used to crystallize the next batch. Simultaneously, in order to evaluate the 
physical stability at high relative humidity, every single batch is analyzed by the GVS 
method combined with PXRD and TGA analysis that were performed before and after 
GVS. The final crystallization step of the synthesis is adjusted until a stable solid form can 
be reproducibly crystallized. The key variables were the water content of the 
crystallization solvent and the drying conditions. 
  
 
 
45 
 
Figure 11 Flowchart for early polymorphism and solvatomorphism tendency and stability 
evaluation of a new drug candidate.(Modified from Publication I). 
5.1.2 Solid-state forms of the new drug candidate and relative stability of the 
discovered forms, I 
On the basis of the PXRD measurements and complementary analysis of the batches by 
TGA, DSC and GVS (I, Table 1, Figs. 3, 6 and 7), the following three crystalline solid 
forms of ORM10921∙HCl were identified: (i) anhydrate I (AHI), (ii) anhydrate II (AHII), 
and (iii) hemihydrate I (HH). 
The two anhydrous forms, AHI and AHII, have been obtained by crystallization from a 
dry solvent, applying all possible precautions to avoid any contact of the sample with 
atmospheric moisture. The anhydrous nature of the forms was verified by TGA analysis (I, 
Table 1). The forms have different melting points and enthalpies (for AHI, Tonset=199 ºC 
and ΔHf = 65 J/g, and for AHII, Tonset = 210 ºC and ΔHf = 80 J/g). Moreover, they were 
found to be readily further differentiated by distinctive profiles of the moisture sorption 
isotherms (I, Fig. 6). Interestingly, despite the crystalline nature of AHI and AHII, the 
moisture-induced phase transitions have been observed for both forms. The critical RH for 
the phase transition was 40-60% for AHI and 93% for AHII. Similar to the case of the 
predominantly amorphous initial material, the crystalline phase resulting from this phase 
transformation was identified to be HH in all cases (I, Table1). 
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A common tendency of all amorphous and anhydrous forms to undergo solid-phase 
transformation into HH suggests that HH has a higher physical stability. This makes HH 
attractive in view of pharmaceutical applications. The formation of the desired HH form 
was achieved from a mixture of ethyl acetate and water. The GVS analysis of batches B6-
B8 has proven that HH is indeed a stable crystalline material (I, Fig.6).  
In order to facilitate the process of the solid form selection for the early drug 
development, the stability relationships between the four discovered solid forms of 
ORM10921∙HCl — amorphous form (AM), anhydrate I (AHI), anhydrate II (AHII), and 
hemihydrate (HH) — has been deducted on the base of the study. Overall, with respect to 
physical stability, these solid-state forms can be ordered at ambient conditions as follows: 
HH > AHII > AHI > AM. In fact, due to the superior relative stability of HH, the other 
three forms exhibited a tendency to convert into HH at high relative humidity, as 
schematically illustrated in Figure 12. Furthermore, comparison of thermal properties of 
the two anhydrous forms revealed higher melting temperature and melting enthalpy of the 
form AHII. In accordance with the Burger-Ramberger rule, this is an indication of 
monotropically related polymorphs, with the form AHII being the most stable anhydrous 
form at all temperatures. 
 
Figure 12 Schematic representation of the relative stability between the discovered solid forms 
of ORM10921∙HCl. (Modified from Publication I). 
5.1.3 Insights into relationship between the structure and the properties, I 
The single-crystal X-ray diffractometry showed that, in the HH crystal (I, Fig. 5B), water 
molecules play the role of binding agents, connecting two different host molecules via the 
H-bond with Cl

. To gain insight into the hydrate formation by ORM10 21∙HCl, the 
Cambridge Structure Database (CSD) search was performed for hydrates of HCl salts of 
organic molecules that contain a tertiary N atom and only ether’s O atoms as H-bond 
acceptors. This research revealed that, in all such molecules, Cl

 is the only structural 
element participating in the formation of H-bonds with water. Furthermore, Cl

 was found 
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to be able to accept as many as six H-bonds. This ability of Cl

 is exemplified, for 
instance, by the crystal structure of VORMEU (CSD reference code). In addition, water 
molecules are prone to form their own hydrogen bonding networks. Taking into account 
these factors, one could expect to find also the hydrates with higher numbers of water 
molecules. However, only the lowest hydrate form, the hemihydrate (HH), was discovered 
in this study. In conclusion, the above structural considerations suggest that a 
comprehensive polymorph and solvate screenings should be performed at the later 
development phases of the project in order to discover all possible solid-state forms of 
ORM10921∙HCl. 
5.2 Salt-cocrystal continuum for itraconazole, II-IV 
Itraconazole (ITZ) is an antifungal drug invented by Janssen Pharmaceutica in 1984. The 
commercial name of this drug is Sporanox. The physical and chemical properties of ITZ 
are similar to many other important drug candidates: high lipophilicity logP = 6.2, very 
weak basicity pKa = 3.7, high molecular weight Mv = 705.6 g/mol, lack of H-bond donors 
in the structure, and low solubility in aqueous media. This makes ITZ an excellent model 
molecule for diverse pharmaceutical studies. 
5.2.1 Reinspection of the weak bonding interactions in itraconazole: 
succinic acid cocrystal and neat itraconazole, II 
In 2003 Remenar et al. have obtained ITZ cocrystals with 1,4 - dicarboxylic acids that 
exhibited significantly enhanced water solubility compared to that of the parent drug. In 
addition, a supramolecular trimer of the ITZ-succinic acid 2 (Figure 13) has been 
discovered. The trimer was considered as a valuable example of a molecular fitting 
mechanism in crystal engineering. It is remarkable that the interaction between succinic 
acid and the strongest basic group of ITZ (piperazine moiety) was not present in the co-
crystal structure (Remenar et al. 2003). Instead, the COOH-group of succinic acid was 
found to be connected to a 1,2,4-triazole group, which was not an expected result.  
During the course of our investigations of the cocrystal of ITZ and succinic acid it has 
been noticed that the modeled cocrystal structure (CSD:12 IKEQEU) has its carbon, 
hydrogen, and nitrogen atoms wrongly placed in the 1,2,4-triazol-5-one ring. In addition, 
we noted that the structure (CSD: TEHZIP) of the neat ITZ has been determined at room 
temperature (RT) with a quite limited resolution. These aspects prompted us to undertake 
additional investigations of the cocrystal and the neat ITZ and reaffirm the existence of the 
trimer in the cocrystal. 
To correct chemical composition of the triazolone ring in the cocrystal, the relevant 
chemical elements have been properly defined in our new structure model. Then, an 
enhanced disorder model has been proposed by us for both the compounds along with a 
proper interpretation of the corresponding intermolecular interactions. In this model we 
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suggested a tilt of triazolone ring (highlighted by yellow in Fig. 13) in addition to a 
disorder in the sec-butyl groups presented in conventional models.  
 
 
Figure 13 Supramolecular trimer unit formed by H-bonding between the-COOH moieties of 
succinic acid and 1,2,4-triazole groups of itraconazole and the discovered halogen 
bonds between the tilted triazolone and dichlorophenyl groups of itraconazole 
 
Our results confirmed that the neat ITZ crystallizes in a triclinic crystal system that 
shows two conformationally distinct molecules A and B in the asymmetric unit (II, Figure 
2b). The main difference between the conformations lies in their methoxyphenyl-
piperazine moiety that is tilted in the B conformation by about 90°, in contrast to the 
phenyl ring adjacent to a piperazine. It can also be noted that the geometries of various 
homo- and heterocyclic rings in the structure are consistent with the ring geometry 
reported earlier (folded dioxolane and chair-like piperazine). However, for the neat ITZ, 
new interesting structural features associated with the intermolecular interactions in the 
crystal lattice were found. As an example, we have found weak halogen bonding contacts 
(Cl1c···O17c = 3.01 Å and 3.08 Å at -150 and 0 °C, respectively) that take place between 
dichlorophenyl and dioxolane groups in a dimeric arrangement (II, Figure 3a). These 
contacts are revealed only between two adjacent molecules of the B conformation, 
whereas in a combination A-A, the contact distances remain outside the boundaries of 
halogen bond criterion, being about 3.8 Å. In addition to the halogen bonding contacts, 
only a weak H-bonding interaction C−H···N exists between triazole and triazolone rings. 
Furthermore, there is a weak face-to-edge π−π stacking network formed via phenyl and 
methoxyphenyl groups of neighboring molecules. The π−π stacking is enabled by the ~90° 
tilt of the methoxyphenylpiperazine moiety of the B conformation.  
Our results also confirmed that the ITZ−succinic acid cocrystal underwent 
crystallization in a monoclinic crystal system that shows a single ITZ molecule with a half 
of the succinic acid molecule in the asymmetric unit. Thus, the formation of the 
supramolecular trimer, in which succinic acid is hydrogen-bonded between two ITZ 
molecules (II, Figures 2 and 3), was verified. Moreover, the lack of the H-bonding 
interaction between the most basic group of ITZ (piperazine) and succinic acid was 
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confirmed. On the other hand, in the original structure, the misplaced C−H formed an 
exceptionally short artificial contact with a neighboring sec-butyl group (the mean H···H 
distance 1.821 Å). In our structure, with a proper determination of the positions of the 
C−H and N atoms and with an enhanced disorder model, the halogen bonding contacts 
(C−Cl···N (Cl1···N41b) 2.836(15) Å and 2. 7(2) Å at -150 and 0 °C, respectively) were 
discovered between the disordered triazolone ring and the dichlorophenyl group of the 
neighboring ITZ molecule (II, Figure 3b), and no artificial short contacts have been found. 
Therefore the observed halogen bonding in conjunction with the stronger H-bonding with 
succinic acid is responsible for the packing of the trimers in the solid-state self-assembly 
of the cocrystal. The π-stacking occurring in the neat ITZ is not present in the cocrystal, as 
trimeric units are packed in rows along the b axis and these rows are parallel to the a axis.  
5.2.2 Preliminary molecular modeling, III 
Complementarities between functional groups and a host-guest geometric fit are the key 
prerequisites for a successful cocrystal formation (Aakeröy et al. 2012). As we have 
confirmed in the Publication II, in the supramolecular trimer of ITZ-SUC the guest 
molecule of succinic acid is located in a pocket formed by two ITZ molecules and H-
bonded with the 1,2,4-triazole groups, serving as a bridge between the two host molecules 
(Fig. 14). We assumed that similar supramolecular motifs can exist in other cocrystals of 
ITZ with C4 dicarboxilic acids. In our structural considerations we have assessed the 
possibility to obtain analogous supramolecular trimers between ITZ and other dicarboxylic 
acids by systematically replacing the SUC with dicarboxylic acids of varying carbon chain 
lengths. Initially, the succinic acid was replaced with one of the dicarboxylic acids and 
then the ITZ molecules were added to the acid so that the H-bonding and ITZ geometry 
stays the same as in the ITZ-SUC cocrystal. The conformations of dicarboxylic acids (III, 
Figure 3 b-e) used in this study were selected in a way that ensures the pocket geometry of 
ITZ-SUC in the model structures. Here we exploited a mix and match strategy described 
in (Aakeröy et al. 2012). Based on these structural considerations, we have concluded that 
the geometries similar to that of ITZ-SUC trimer can be realized with a variety of 
dicarboxylic acids as guest molecules. It should be noted, however, that the formation of 
such trimers with the odd-chain dicarboxylic acids requires a significant departure from 
their minimal energy conformation, as the latter is characterized by an angle of 
approximately 120° between the two –OH groups (Aakeröy et al. 2012; Gopalan et. al. 
2000). In contrast, the even-chain dicarboxylic acids are known to have the minimum 
energy conformation with the –OH groups arranged in a collinear fashion (Gopalan et. al. 
2000; Aakeröy et al. 2012). As a result, the replacement by a dicarboxylic acid with an 
even number of carbon atoms allowed a trimer formation using the conformation of the 
acid with minimum energy. This suggests a higher probability of the cocrystal formation 
with these acids. 
In the previous subsection we have shown that the revised structures revealed the 
presence of weak halogen bonding as one of the important non-covalent interactions in 
ITZ-SUC cocrystal (N…Cl) (Fig.13) as well as in neat itraconazole (O…Cl).  
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Figure 14 The examples of hypothetic trimers that can be formed between itraconazole and 
dicarboxylic acids with varying carbon chain length. 
Our modeling suggested that the length alteration of the carbon chain of acids forming the 
trimer leads to a shift of the relative position of the itraconazole molecules in opposite 
directions. This shift changes the outer size and the geometry of the supramolecular trimer 
and, as a result, may significantly alter the weak halogen-bonding network between the 
trimers in the ITZ cocrystals. Since weak van der Waals interactions and halogen bonds 
both participate in bonding and stabilizing the trimers in the cocrystal, it is difficult, if not 
impossible, to predict whether or not these virtual trimers would eventually form a 
periodic crystalline structure. 
5.2.4 Obtaining cocrystals and salts of itraconazole, III-IV 
Screening for cocrystals of itraconazole and dicarboxylic acids, III 
According to the structural considerations, ITZ should be able to form cocrystals with 
dicarboxylic acids that have an even number of carbon atoms in the chain. To verify this 
hypothesis we have performed an experimental screening that employs dicarboxylic acids 
of varying chain length (C2-C10), including also those that have an odd number of carbon 
atoms. The experimental protocol and decision tree used in our cocrystal screening. 
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approach is introduced in the Fig.15. In order to maximize the number of possible hits, we 
used both mechanochemical synthesis by solvent assisted grinding and slow evaporation 
techniques (Sheikh et al. 2009) and we made both 1:1 and 2:1 (ITZ: coformer) mixtures of 
the components. The physical and chemical analyses of the prepared substances were 
performed by using the same methodology focused on disclosing and thorough 
investigation of the nature of new crystalline compounds.  
The success and advantage of the solvent drop-grinding technique in synthesis of 
cocrystals, as discussed, e.g., in (Chiarella et al. 2007), is mainly due to the low amount of 
solvent. This observation dictates that the crystallization takes place in a region of the 
phase diagram in which the co-crystal is more likely to be a stable solid phase. The 
previously reported unsuccessful attempts to obtain the cocrystal of ITZ and MAL were 
based on high throughput crystallization from solution that at least requires the ternary 
phase diagram to be taken into account (Chadwick et al. 2009). Thus, in our slow 
evaporation crystallization experiments we used the mixture of CLF and THF that allows 
achieving of the congruent crystallization due to comparable solubility of both 
components in this solvent mixture. 
In the experiments, we have indeed obtained cocrystals of ITZ with oxalic (C2) and 
adipic (C6) dicarboxylic acids, of which two are cocrystal solvates (ITZ-OXA-ACE and 
ITZ-OXA-THF) and one a hydrate (ITZ-ADI-H2O). Then, to our surprise, we have 
succeeded in obtaining the cocrystals of ITZ with the malonic (C3), glutaric (C5), and 
pimelic (C7) acids, which have an odd number of carbon atoms in the chain. These 
cocrystals are ITZ-MAL, ITZ-GLU, and ITZ-PIM. However, we could not obtain 
cocrystals of ITZ with the C8-C10 dicarboxylic acids. Also, the solvent assisted milling of 
ITZ with azelaic (C9) acid resulted in a mixture of pure ITZ and alpha polymorphic form 
(Form II) of azelaic acid reported in (Housty 1967). 
In terms of cocrystal generation, both screening methods - solvent assisted milling and 
slow evaporation – were equally successful. The main difference between the methods is 
that they yielded different cocrystal solvates, which is solely attributed to the different 
solvents employed during the experiments, as in the case of ITZ cocrystals with oxalic 
acid. In addition, the slow evaporation experiments were able to produce ITZ-ADI-H2O, 
while the solvent assisted milling resulted in a physical mixture of ITZ and ADI only. 
On the other hand, the solvent assisted milling experiments of ITZ and the GLU acid 
in 1:1 and 2:1 ratios indicated the existence of a ITZ-GLU cocrystal of a different 
stoichiometry (1:2), which was not achieved in the crystallization experiments. 
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Figure 15 The decision tree used for screening experiments.  
The detail description of the properties of the new cocrystals can be found in Publication 
IV and in the upcoming section 5.3.  
The results demonstrate that employing the combined screening approach, where the 
two most popular experimental techniques (Sheikh et al. 2009) and various ratios of the 
components are used, is feasible in order to maximize the number of hits. The initial 
screening performed by (Remenar et al. 2003) used only high-throughput screenings that 
were based on evaporative crystallization, in which the choice of solvents and the 
knowledge of the phase diagram are vital for a success. Using this combined approach we 
have obtained seven multiple component compounds (Table 3). Six of them have not been 
reported in the scientific literature before. 
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Hydrochloride salts of itraconazole, IV 
In order to enable comparison of the properties of the ITZ cocrystals with ITZ salts we 
have prepared ITZ hydrochloride salts using two traditional approaches described in the 
section 4.2.2 by gas bubbling and reaction crystallization methods. Unexpectedly, we have 
obtained two different salt forms. First, the ITZ dihydrochloride (denoted ITZ∙2HCl, 
stoichiometry verified by elemental analysis) showed unique PXRD pattern different from 
the known ITZ dihydrochloride. Secondly, the new ITZ trihydrochloride (denoted 
ITZ∙3HCl, stoichiometry verified by elemental analysis) was obtained in the gas bubbling 
experiments. The detailed description of the properties of the salts can be found in 
Publication IV and in the upcoming section 5.3.  
5.2.5 Solid-state properties of salts and cocrystals of itraconazole, III-IV 
Table 3 summarizes the solid state properties of the multiple component compounds 
discovered in our experiments. The unique PXRD patterns of the salts, cocrystals and 
ternary compounds are shown in (III, Fig. 5 and IV, Fig. 3a).  
More specifically, two new cocrystals of ITZ and C3 and C5 dicarboxylic acids were 
obtained as a pure phase in both grinding and slow evaporation experiments. First, ITZ 
and malonic acid (C3), denoted ITZ-MAL, 2:1, had the same stoichiometry, determined 
by NMR, as the known cocrystal of ITZ and succinic acid (ITZ-SUC, 2:1).  Second, the 
cocrystal of ITZ and glutaric acid C5 (ITZ-GLU), surprisingly, has substantially different 
stoichiometry 1:2. The pure ITZ-GLU was obtained from additional experimental cycle 
using 1:2 molar ratio of ITZ to acid by both evaporation and grinding experiments. All 
three cocrystals had different melting points. Interestingly, the melting points of the ITZ-
MAL and ITZ-SUC lies between the melting points of neat ITZ and the coformer. 
However, the melting point of the ITZ-GLU is lower then the melting points of both 
components (table 3). In addition, the empirical evidence of existence of the ITZ and 
pimelic acid C7 cocrystal (ITZ-PIM) has been demonstrated. However, the stoichiometry 
and physical properties of the ITZ-PIM were not possible to study, since the form has not 
been obtained as a pure phase.  
Furthermore, three new ternary component compounds were obtained. Two solvates of 
ITZ and oxalic acid C2 cocrystals with acetone (obtained by solvent assisted milling) and 
tetrahydrofurane (obtained by slow evaporation) denoted ITZ-OXA-ACE (1:1:0.5) and 
ITZ-OXA-THF (1:1:1), respectively. Last, the hydrate of ITZ and adipic acid C6 cocrystal 
denoted ITZ-ADI-H2O (1:1:1.3) was obtained in slow evaporation experiments. The 
stoichiometry and solvation nature of the materials were verified by TGA coupled with 
MS analysis. The solvent displacement by drying or moisturizing failed, leading to 
collapse of the crystalline structure for all solvates. 
No cocrystals were formed between the  ITZ and C8-C10 acids, which are suberic, 
azelaic and sebacic acids. In the publication III, subsections 3.3.1-3.3.3, the results are 
described in more details individually for each drug-coformer combination. It must be 
noted that NMR and HPLC showed no signs of degradation in all samples analyzed. 
  
 
 
54 
Table 3. Solid state properties of salts and cocrystals of itraconazole (Modified from III 
and IV). 
Cocrystal/ 
Cocrystal solvate 
 
Number of 
carbons 
Stoichio- 
metry 
Co-
former 
Mp, °C 
Co-crystal 
Mp 
(Desolvation/ 
Desproportionati
on T ) °C 
Weight loss 
on drying, 
% 
De-
solvation 
product 
 
ITZ-MAL (III, 
IV) 
3 2:1 134 148 0 n.a. 
ITZ-SUC (III,IV) 
4 2:1 186 157 0 n.a. 
ITZ-GLU (III) 
5 1:2 98 94 0 n.a. 
ITZ-PIM (III) 
7 n.a. 104 n.a. 0 n.a. 
ITZ-ADI-H2O 
(III) 
6 1:1:1.3 153 (80) 2.8 Am 
ITZ-OXA-
ACE(III) 
2 1:1:0.5 189 (81) 3.4 Am 
ITZ-OXA-THF 
(III) 
2 1:1:1 189 (100) 7 Am 
ITZ∙2HCl (IV) - 1:2 -114.9 (90)2 10.8 n.a. 
ITZ∙3HCl (IV) - 1:3 -114.9 (90) 2 11.2 n.a. 
 
The hydrochlorides ITZ∙2HCl and ITZ∙3HCl were white crystalline powders with 
unique PXRD patterns (IV, Fig 3a) different from the ITZ dihydrochloride reported in 
literature (Remenar et al. 2003; Tao et al. 2009). None of the salts, however, exhibited any 
DSC endotherm attributable to the melting. Instead, the slow loss of weight started as low 
as at T > 40 ºC with a considerable rate increase at T > 90 ºC and between 90 and 250 ºC 
equals 10.8% and 11.2% for ITZ∙2HCl and ITZ∙3HCl. The increase in the weight loss rate 
corresponds to the first broad endotherm observed in the DSC thermograms for the salts 
(IV, Fig. 3b). Moreover, the MS analysis performed simultaneously with TGA indicated 
the evaporation of only Cl ion that correlates with the weight loss kinetic giving the firm 
evidence of disproportionation of the salt. The revealed thermal behavior of ITZ 
hydrochloric salts is similar to that of the ITZ dihydrochloride described previously (Tao 
et al. 2009). 
Such variety of ITZ hydrochlorides is likely due to its very weakly basic properties as 
well as molecular structure with multiple proton accepting sites that probably leads to 
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variability of HCl location in the solid state. This fact makes it challenging to establish a 
robust process of crystallization of a certain form. 
5.2.6 Molecular insight into formation of itraconazole multicomponent 
compounds with dicarboxylic acids, III  
In order to gain insight into the obtained new non-solvated crystalline forms, an 
experimental analysis combining 13C cross-polarization magic-angle spinning (CPMAS), 
solid-state NMR (SSNMR), and Raman spectroscopy was performed (Elbagerma et al. 
2010; Vogt 2010).  In this study, 13C CPMAS NMR and Raman spectra of the cocrystals 
were compared with those of the pure ITZ and dicarboxylic acids.  
In solid forms, most carboxylic acids appear as H-bonded chains in all polymorphic 
forms, where the carboxyl groups of one molecule are H-bonded to the carboxyl groups of 
the neighboring molecules, so that  C=O groups act as acceptors and  OH groups as donors 
(Gopalan et al. 2000). In the known ITZ-SUC cocrystal, the supramolecular trimer 
consists of two ITZ molecules that are H-bonded to succinic acid in such a way that the 
C=O group of the acid is free of H-bonds, but the –OH group is connected to the 1,2,4,-
triazol group of ITZ (Fig. 13). This implies that, in the Raman spectrum of the cocrystal, 
the C=O stretching vibration must be shifted to a higher wavenumber (Socrates 2004). 
Indeed, the C=O peak observed in the Raman spectra of SUC at1653 cm-1 is shifted to 
1719 cm-1 in the ITZ-SUC spectrum (III, Fig.6). Moreover, in the SSNMR, the 13C 
signal from carbonyl (C=O) in succinic acid (180.0 ppm) showed an upfield shift (175.0 
ppm) of 5.0 ppm (III, Fig. 7). The neat malonic acid displayed a doublet resonance pattern 
(C=O at 174.7, 174.3 ppm) due to the presence of two non-equivalent H-bonding schemes 
in the crystal: an intramolecular and an intermolecular35. Similarly, in the Raman spectra 
of the neat malonic acid, two peaks attributed to the C=O vibrations are seen at 1650 cm
-1
 
and 1680 cm
-1
 (III, Fig. 6). Interestingly, the ITZ-MAL cocrystal resulted in a singlet 
resonance pattern with the carbonyl signal showed an upfield shift (169.0 ppm) of 5.7 
ppm. Also, in the Raman spectra of ITZ-MAL, there is a shift of the C=O vibration to a 
higher wavenumber (1730 cm
-1
). In addition, the neat ITZ shows a doublet resonance 
pattern in its solid state NMR attributed to the presence of two non-equivalent molecules 
in an asymmetric unit of the crystal lattice (III, Nonappa et al. 2013).  The cocrystal with 
succinic acid (ITZ:SUC) shows a significant change in the SSNMR spectra exhibiting a 
singlet resonance pattern that indicates the presence of one molecule of ITZ in an 
asymmetric unit. These results are consistent with the single crystal X-ray studies (III, 
Nonappa et al. 2013). The cocrystals obtained with malonic acid also showed a similar 
change in the SSNMR.  Overall, the 13C CPMAS spectra of ITZ-MAL are very similar to 
the ITZ-SUC.  This clearly illustrates a similarity of the ITZ:SUC and ITZ:MAL cocrystal 
structures, which is a remarkable result. 
Furthermore, in Raman and CPMAS NMR spectra of all cocrystals and cocrystal 
solvates discovered in this work (III, Figs. 6 and 7), we have noticed the shifts of the C=O 
vibration peak to a higher wavenumber (in Raman spectra) and upfield shifts of the 13C 
signal from the carbonyl (C=O) of the carboxylic acids (in CPMAS NMR spectra). This is 
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an indication of the absence of the H-bonding between the C=O and OH groups due to 
formation of a complex with ITZ. However, the other cocrystals and cocrystal solvates has 
the SSNMR spectra that are distinctive from the ITZ-SUC and ITZ-MAL due to a 
different stoichiometry.  
Most importantly, C7 was identified as the maximum carbon atom number of the 
aliphatic chain for the successful cocrystallization reaction between ITZ and a 
dicarboxylic acid. In terms of supramolecular structures, two families of the ITZ 
cocrystals were recognized: (1) the cocrystals built of the trimer characteristic of ITZ-
SUC, and (2) the cocrystals that are not able to form similar synthons. These results 
demonstrate that a preliminary molecular modeling, with only one conformation of ITZ 
being considered (the one that is realized in ITZ-SUC), is not enough for a reliable 
prediction of obtainable cocrystals of ITZ and aliphatic dicarboxylic acids, as these 
molecules are rather complicated and conformationally flexible. Such modeling, however, 
might still help to find the direction of searching for probable successful hits.  
5.3 Pharmaceutical properties of cocrystals and salts of 
itraconazole, IV 
This subsection deals with the properties of the neat ITZ, two cocrystals ITZ-MAL and 
ITZ-SUC and two new hydrochloric salts ITZ∙2HCl and ITZ∙3HCl with main focus put on 
the hygroscopicity, stability (including disproportionation) and intrinsic dissolution.  
5.3.1 Hygroscopicity and relative thermodynamic stability at ambient 
conditions, IV 
In order to evaluate the hygroscopicity and compare the thermodynamic stabilities of the 
cocrystals and salts at ambient conditions the GVS method was used. Commercial ITZ, 
being a hydrophobic, non-porous, and crystalline material, shows very low hygroscopicity 
(IV, Fig. 4a). The two cocrystals, ITZ-SUC and new ITZ-MAL, exhibited a quite similar 
non-hygroscopic behavior comparable with that of the commercial ITZ (IV Fig. 4a). The 
GVS sorption-desorption isotherms were reversible, showing almost no hysteresis.  
In contrast, both ITZ hydrochloric salts are highly hygroscopic at RH > 70 % (IV, Fig 
4b). No deliquescence was observed with ITZ∙2HCl under the conditions of the 
experiments. The ITZ∙3HCl exhibited higher moisture uptake at RH > 75 %. Moreover the 
deliquescence occurred, and the sample transformed into a highly viscose transparent 
substance. This change was irreversible and the sample mass decreased by 3 % after the 
desorption indicating an instability of the salt. 
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5.3.2 Solubility and intrinsic dissolution rate (IDR), IV 
The apparent solubility of all substances at T = 37 ºC in the dissolution medium was 
determined by the shake–flask method before the IDR method had been developed (table 
4). A 10-mg sample equilibrated for 3 days with 20 ml of the buffer.  
The intrinsic dissolution profiles within the first 30 min of the studied systems are 
shown in publication IV (Fig. 5). The calculated IDR are presented in Table 4. The highest 
 
Table 4. Properties of itraconazole solid forms studied.(Modified from IV) 
Solid 
form 
Melting 
temperature 
Disporoportionation 
(Decomposition) 
temperature 
IDR Solubility Relative 
kinetic 
stability 
ºC ºC pH 1.2, µg min
-1 
m
-2 
µg/mL grades 10-0 
ITZ 169 n.o. 0.95 5 10 
ITZ∙2HCl 90 90 45.9 26 5 
ITZ∙3HCl 90 90 35.4 74 3 
ITZ-SUC 157 n.o. 11.0 18 10 
ITZ-MAL 148 148 4.5 17 10 
 
IDR was observed for the both hydrochloric salts (ITZ∙2HCl and ITZ∙3HCl). The superior 
IDR and solubility demonstrated by hydrochloride is obviously due to ITZ being 
protonated (subsection 5.2.5 and IV, SI). The dissolution rate of ITZ-SUC cocrystal was 
~11-folds higher than the dissolution rate of the commercial ITZ. Finally, the new ITZ-
MAL cocrystal exhibited ~5-fold higher IDR in relation to ITZ. 
5.3.3 Water induced transitions and stability of itraconazole salts and 
cocrystals, IV 
To reveal possible solid-phase transitions induced by moisture, the GVS and IDR tests 
were combined with PXRD analysis performed before and after the experiments. 
Comparison of PXRD patterns before and after GVS and IDR revealed no structural 
changes in the ITZ-MAL and ITZ-SUC cocrystals as well as in commercial crystalline 
ITZ. However, the PXRD pattern measured after the GVS showed ITZ∙2HCl to transform 
into another solid form (IV, Fig. 6a). Similarly, the PXRD pattern of ITZ∙2HCl, acquired 
after the IDR experiments, proves that the salt undergoes a phase transformation during 
the dissolution. The resulting solid form is identical to the one found after the GVS 
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experiments, and is presumably a hydrate of the ITZ hydrochloric salt. Furthermore, after 
30-60 min after the dissolution test was initiated, gas bubbling was noticed on the surface 
of disc of the ITZ∙3HCl samples. The PXRD analysis performed after the IDR 
experiments indicates a complete amorphization of the ITZ∙3HCl sample (IV, Fig. 6b). We 
presume that this phenomenon is caused by the HCl gas liberation from the samples 
during the IDR experiments. This phenomenon once again refers to instability of 
ITZ∙3HCl under the experimental conditions. Moreover, the same amorphization took 
place in the GVS experiment (IV, Fig. 6b), which proves that the effect is triggered upon 
the contact with water molecules. Since we have noticed the disproportionation of both 
salt forms upon heating (Table 3 and 4) the possible explanation for such phenomenon 
could be a disproportionation of the salt (Stephenson and Taylor 2011). 
Overall, based on the obtained results, it is possible to rank the studied forms in terms 
of relative thermodynamic stability at ambient conditions as follows (grades 10-0): 10 ITZ 
≈ 10 ITZ-SUC ≈ 10 ITZ-MAL > 5 ITZ∙2HCl > 3 ITZ∙3HCl. Interestingly, the same 
ranking between the studied forms is possible to establish on the basis of the DSC results. 
The ITZ having a highest melting point (Tm,onset = 169 °C) and zero weight loss is leading, 
followed by cocrystals ITZ-SUC (Tm,onset = 157 °C) and ITZ-MAL (Tm,onset = 148 °C). 
These solid forms exhibit a very high thermal stability and are stable also at high relative 
humidity. Therefore, they can be used in formulation without any special stabilizing. In 
the contrast, the two hydrochlorides of ITZ are not stable upon heating and decompose at 
T > 90 ºC. Such instability of the ITZ hydrochloric salts can lead to numerous difficulties 
in establishing a robust formulation based on them. 
Among the solid-state forms reported in this work, the cocrystals ITZ-SUC and ITZ-
MAL are most promising in view of pharmaceutical applications, since they do enhance 
the dissolution rate of ITZ and yet exhibit superior stability. The study demonstrates that 
for any weak bases, cocrystallization is a more suitable approach, as compared with 
hydrochloric salt formation.  
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6 Summary and conclusions 
(1) Fast and cost-effective assessment of polymorphism and solvatomorphism 
tendency and physical stability of the new drug candidate ORM10921 hydrochloride has 
been accomplished. Three new crystalline forms, including two anhydrous and one hemi-
hydrate, have been discovered. The relative stability of the discovered solid forms at 
ambient conditions was established, and the most stable form was found to be the 
hemihydrate. The single-crystal structure revealed the Cl- atom to be responsible for 
hemihydrate formation. The procedure can be recommended for the evaluation of the 
polymorphism and solvatomorphism tendency of hydrochlorides salts of new chemical 
entities (“precandidates”) even prior to the final selection of the drug candidate.  
 (2) In order to enable molecular modeling simulations the more accurate crystalline 
structures of both neat itraconazole (ITZ) and itraconazole-succinic acid (ITZ-SUC) 
cocrystal were revealed. A weak halogen bonding in the crystals has been found. The 
molecular modeling simulations have been performed. The experimental results 
demonstrate that a preliminary molecular modeling, with only one conformation of ITZ 
being considered (the one that is realized in ITZ-SUC), is not enough for a reliable 
prediction of obtainable cocrystals of ITZ and aliphatic dicarboxylic acids, as these 
molecules are rather complicated and conformationally flexible. Such modeling, however, 
still helps to find the direction of searching for probable successful hits. Together with the 
screening technology, this approach can considerably improve the cost efficacy and 
probability of the success.   
(3) The optimal salt and cocrystal screening approach based on mechanochemistry 
synthesis and slow evaporation was used to reveal 9 new multicomponent crystalline solid 
forms. We have systematically studied cocrystallization of ITZ with a range of aliphatic 
dicarboxylic acids. Most importantly, C7 was identified as the maximum carbon atom 
number of the aliphatic chain for the successful cocrystallization reaction between ITZ and 
a dicarboxylic acid. In terms of supramolecular structures, two families of the ITZ 
cocrystals were recognized: (1) the cocrystals built of the trimer characteristic of ITZ-SUC 
and (2) the cocrystals that are not able to form similar synthons. Overall, our work 
demonstrates a wide diversity of ITZ cocrystals with aliphatic dicarboxylic acids having a 
variety of the carbon chain lengths. This finding has a considerable conceptual and 
practical value in the field of crystal engineering, putting an additional emphasis on the 
importance of the weak intermolecular interactions in the crystal structure cohesion. 
(4) The comparative study of the pharmaceutical properties of the new ITZ salts di- 
and tri-hydrochlorides and new ITZ-malonic acid (2:1) cocrystal has been performed. The 
intrinsic dissolution rate, hygroscopicity, and thermodynamic stability were determined 
for the obtained solid-state forms and compared to those of the ITZ-SUC (2:1) cocrystal. 
The results showed that the forms with higher dissolution rates are less stable. The 
reported research demonstrates that, for weak bases, cocrystallization is a more suitable 
approach to the dissolution rate enhancement of poorly water-soluble drugs, as compared 
with the conventional hydrochloric salt formation. 
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